Vienna biotech Cel-Sci faces delisting threat on heels of lawsuit win
July 16, 2018 at 15:12 PM EDT
The Vienna biotech must submit a plan by Aug. 13 to maintain its New York Stock Exchange listing. And it must regain compliance within five months after that.
